Novartis Acquires Pikavation for Up to $3 Billion in Cancer Pipeline Expansion
Novartis will acquire Pikavation Therapeutics for up to $3 billion to gain its PI3Kα inhibitor programs, led by SNV4818 for metastatic breast cancer. The deal includes $2 billion upfront and up to $1 billion in milestones, with completion expected in first half 2026. SNV4818 is designed to selectively target mutated PI3Kα while sparing healthy cells.
Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor programs designed to treat forms of cancer. The transaction is expected to be finalized in the first half of 2026, subject to completion of review under antitrust laws.
Pikavation’s programs are led by SNV4818, a pan-mutant selective PI3Kα inhibitor currently in early-stage clinical trials for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer and other solid tumors. SNV4818 is designed to target the mutated PI3Kα enzyme found in cancer cells while sparing wild-type PI3Kα in healthy cells, unlike currently available PI3Kα inhibitors that block both mutant and wild-type PI3Kα, leading to tolerability challenges for patients.
By focusing on the mutated form in tumors, SNV4818 aims to reduce unwanted side effects, support more consistent dosing, and make it easier to combine with hormonal therapy and other treatments earlier in care. Preclinical studies have shown strong activity against common PIK3CA mutations and clear selectivity over the normal enzyme.
SNV4818 is now being evaluated in a Phase I/II open-label dose escalation and expansion study as a monotherapy and in combination with fulvestrant and palbociclib, a combination therapy that is standard of care for HR+/HER2- breast cancer. The trial’s estimated primary completion date is April 2027.
Novartis reasons that by targeting PI3Kα, it can reduce the approximately 40% of HR+/HER2- breast cancer patients who potentially face worse disease prognosis due to the presence of PIK3CA mutations in their tumors. Novartis has agreed to solely oversee future development and commercialization of SNV4818 and other PI3Kα inhibitor programs.
In return, Novartis agreed to pay Synnovation $2 billion cash upfront and up to $1 billion in payments tied to achieving development, regulatory, and commercial milestones. Synnovation will continue advancing other programs in its R&D pipeline, including the selective PARP1 inhibitor SNV1521 and other oncology and immunology programs, and will continue operating as an independent entity.
Separately, Novartis Pharmaceuticals announced a study to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography/Computerized Tomography imaging compared with conventional imaging as standard of truth in patients with neuroendocrine neoplasms and healthy volunteers.